

Shahab Asgharzadeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2638833/publications.pdf>

Version: 2024-02-01

84
papers

7,110
citations

76326

40
h-index

76900

74
g-index

85
all docs

85
docs citations

85
times ranked

9784
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 153-164.	4.2	13
2	Adaptation of Imaging Mass Cytometry to Explore the Single Cell Alloimmune Landscape of Liver Transplant Rejection. <i>Frontiers in Immunology</i> , 2022, 13, 831103.	4.8	4
3	Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy. <i>Pediatric Blood and Cancer</i> , 2022, , e29719.	1.5	0
4	Phase I study of ¹³¹ I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10038-10038.	1.6	2
5	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10003-10003.	1.6	6
6	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. <i>Onc Immunology</i> , 2021, 10, 1838140.	4.6	22
7	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. <i>Nature Communications</i> , 2021, 12, 511.	12.8	85
8	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	1.2	14
9	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
10	Ultra-High Dose Vitamin D in Pediatric Hematopoietic Stem Cell Transplantation: A Nonrandomized Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1001.e1-1001.e9.	1.2	6
11	Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 146-160.	1.5	41
12	Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastoma. <i>Genome Research</i> , 2020, 30, 1228-1242.	5.5	20
13	A genome-wide association study on medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 309-315.	2.9	10
14	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2160-2169.	1.6	98
15	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients 18 months with unfavorable histology and without MYCN amplification: A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10502-10502.	1.6	0
16	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. <i>Pharmaceutical Statistics</i> , 2019, 18, 659-670.	1.3	2
17	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. <i>Journal of Neuro-Oncology</i> , 2019, 145, 375-383.	2.9	7
18	Enhancing Natural Killer and CD8 ⁺ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8 ⁺ T Cells with HLA-E Monospecific Monoclonal Antibodies. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2019, 38, 38-59.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. <i>Cancer Research</i> , 2019, 79, 2208-2219.	0.9	15
20	Role of C-C Motif Chemokine Ligand 2 in Metastatic Neuroblastoma. <i>Journal of the American College of Surgeons</i> , 2019, 229, S217.	0.5	0
21	Cross-Cohort Analysis Identifies a TEAD4-MYC Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. <i>Cancer Discovery</i> , 2018, 8, 582-599.	9.4	119
22	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1084-1093.	6.3	73
23	Rare MYC-amplified Neuroblastoma With Large Cell Histology. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 461-466.	1.0	11
24	MBCL-49. PROGNOSTIC SIGNIFICANCE OF MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IN CHILDREN RECEIVING IRRADIATION-SPARING REGIMENS. <i>Neuro-Oncology</i> , 2018, 20, i128-i128.	1.2	0
25	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYC-Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5673-5684.	7.0	92
26	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	1.8	31
27	NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells. <i>Journal of Immunotherapy</i> , 2017, 40, 265-276.	2.4	86
28	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. <i>Clinical Cancer Research</i> , 2017, 23, 5374-5383.	7.0	38
29	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. <i>Cancer Research</i> , 2017, 77, 5142-5157.	0.9	130
30	TGF β 1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. <i>Clinical Cancer Research</i> , 2017, 23, 804-813.	7.0	98
31	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. <i>Oncotarget</i> , 2017, 8, 91516-91529.	1.8	45
32	MB-53hTERT EXPRESSION AND REGULATION IN PEDIATRIC MEDULLOBLASTOMA (MB). <i>Neuro-Oncology</i> , 2016, 18, iii109.2-iii109.	1.2	1
33	BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma. <i>PLoS ONE</i> , 2016, 11, e0156907.	2.5	7
34	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. <i>Cancer Letters</i> , 2016, 371, 214-224.	7.2	46
35	More than the genes, the tumor microenvironment in neuroblastoma. <i>Cancer Letters</i> , 2016, 380, 304-314.	7.2	64
36	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2016, 18, 126-131.	1.2	69

#	ARTICLE	IF	CITATIONS
37	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
38	Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. Frontiers in Oncology, 2015, 5, 191.	2.8	16
39	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
40	Pediatric Brain Tumor Cell Lines. Journal of Cellular Biochemistry, 2015, 116, 218-224.	2.6	50
41	Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Experimental Cell Research, 2015, 334, 78-89.	2.6	7
42	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
43	CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research, 2015, 75, 3155-3166.	0.9	132
44	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	298
45	MB-34 * MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IDENTIFICATION USING NON-INVASIVE MAGNETIC RESONANCE SPECTROSCOPY. Neuro-Oncology, 2015, 17, iii27-iii27.	1.2	0
46	A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell, 2015, 28, 599-609.	16.8	99
47	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	7.0	92
48	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
49	<i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. Clinical Cancer Research, 2014, 20, 827-836.	7.0	29
50	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research, 2014, 74, 5999-6009.	0.9	9
51	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. PLoS ONE, 2014, 9, e108818.	2.5	6
52	Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clinical Immunology, 2013, 149, 55-64.	3.2	53
53	Trends in childhood brain tumor incidence, 1973-2009. Journal of Neuro-Oncology, 2013, 115, 153-160.	2.9	62
54	Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGF β 1. Cancer Immunology, Immunotherapy, 2013, 62, 1637-1648.	4.2	64

#	ARTICLE	IF	CITATIONS
55	The genetic landscape of high-risk neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 279-284.	21.4	990
56	Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells. <i>Journal of Immunotherapy</i> , 2013, 36, 319-329.	2.4	42
57	Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study. <i>Journal of Clinical Oncology</i> , 2013, 31, 10039-10039.	1.6	0
58	Common Variation at <i>BARD1</i> Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity. <i>Cancer Research</i> , 2012, 72, 2068-2078.	0.9	97
59	Detecting Changes in DNA Copy Number: Reviewing signal processing techniques. <i>IEEE Signal Processing Magazine</i> , 2012, 29, 98-107.	5.6	16
60	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3525-3532.	1.6	236
61	Neuroblastoma: Issues in Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S92-S100.	2.0	20
62	Copy number variation signature to predict human ancestry. <i>BMC Bioinformatics</i> , 2012, 13, 336.	2.6	8
63	Novel Pathways to Erythropoiesis Induced by Dimerization of Intracellular C-Mpl in Human Hematopoietic Progenitors. <i>Stem Cells</i> , 2012, 30, 697-708.	3.2	8
64	IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. <i>Journal of Clinical Investigation</i> , 2012, 122, 2221-2233.	8.2	126
65	TARGETgene: A Tool for Identification of Potential Therapeutic Targets in Cancer. <i>PLoS ONE</i> , 2012, 7, e43305.	2.5	19
66	Bioinformatics for Copy Number Variation Data. <i>Methods in Molecular Biology</i> , 2011, 719, 235-249.	0.9	4
67	Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3506-3515.	1.6	129
68	Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. <i>Bioinformatics</i> , 2010, 26, 807-813.	4.1	28
69	NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. <i>Cell</i> , 2010, 142, 218-229.	28.9	190
70	Microarray classification using block diagonal linear discriminant analysis with embedded feature selection. , 2009, , .		7
71	Joint estimation of copy number variation and reference intensities on multiple DNA arrays using GADA. <i>Bioinformatics</i> , 2009, 25, 1223-1230.	4.1	37
72	ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome. <i>Cancer Cell</i> , 2009, 15, 328-340.	16.8	132

#	ARTICLE	IF	CITATIONS
73	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. <i>Nature Genetics</i> , 2009, 41, 718-723.	21.4	266
74	V α 24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2009, 119, 1524-1536.	8.2	287
75	Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. <i>Pediatric Blood and Cancer</i> , 2008, 50, 312-318.	1.5	125
76	Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. <i>Pediatric Blood and Cancer</i> , 2008, 51, 235-240.	1.5	149
77	An integrated cross-platform prognosis study on neuroblastoma patients. <i>Genomics</i> , 2008, 92, 195-203.	2.9	47
78	Bayesian detection of recurrent copy number alterations across multiple array samples. , 2008, , .		1
79	Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma. <i>New England Journal of Medicine</i> , 2008, 358, 2585-2593.	27.0	271
80	Sparse representation and Bayesian detection of genome copy number alterations from microarray data. <i>Bioinformatics</i> , 2008, 24, 309-318.	4.1	113
81	Wavelet Footprints and Sparse Bayesian Learning for DNA Copy Number Change Analysis. , 2007, , .		13
82	Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. <i>Pediatric Blood and Cancer</i> , 2007, 49, 34-40.	1.5	104
83	Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1193-1203.	6.3	212
84	Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2. <i>Journal of Experimental Medicine</i> , 2004, 199, 1213-1221.	8.5	215